| Literature DB >> 34041241 |
Jingjing Fa1,2, Xiaoqing Zhang1, Xiaoping Zhang1, Ming Qi1, Xingyu Zhang1, Qihua Fu1,2,3, Zhuoming Xu4, Yunqian Gao1,2, Bo Wang1,3.
Abstract
Congenital heart defects (CHDs) are the most common birth defects worldwide. 22q11.2 deletion syndrome is the most common microdeletion disorder that has been frequently associated with conotruncal malformations. By now, the dosage-sensitive gene TBX1 has been adopted as the major pathogenic gene responsible for 22q11.2 deletion, which is regulated by canonical Wnt/β-catenin signaling pathway in heart outflow tract development. Here, we report the long noncoding RNA (lncRNA) lnc-TSSK2-8, which is encompassed in the 22q11.2 region, that can activate canonical Wnt/β-catenin signaling by protecting β-catenin from degradation, which could result from decreased ubiquitination. Such effects were mediated by two short heat shock proteins HSPA6 and α-β-crystallin (CRYAB), whose expression was regulated by lnc-TSSK2-8 through a competing endogenous RNA (ceRNA) mechanism. In clinical practice, the pathogenesis of copy number variation (CNV) was always attributed to haploinsufficiency of protein-coding genes. Here, we report that the 22q11.2 lncRNA lnc-TSSK2-8 significantly activated canonical Wnt/β-catenin signaling, which has major roles in cardiac outflow tract development and should act upstream of TBX1. Our results suggested that lncRNAs should contribute to the etiology of CNV-related CHD.Entities:
Keywords: 22q11.2 deletion; Wnt/β-catenin signaling; congenital heart disease; lnc-TSSK2-8; long noncoding RNA
Year: 2021 PMID: 34041241 PMCID: PMC8141806 DOI: 10.3389/fcell.2021.660576
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
FIGURE 1Full-length characterization and subcellular expression analysis of lnc-TSSK2-8. (A) Electrophoresis analysis of rapid amplification of cDNA ends (RACE) PCR and the obtained full-length cDNA sequence of lnc-TSSK2-8. (B) Subcellular distribution of lnc-TSSK2-8. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and U6 were used for references of cytoplasmic expression and nuclear expression, respectively.
FIGURE 2Overexpression of lnc-TSSK2-8 activates the Wnt/β-catenin signaling pathway. (A) RT-qPCR quantification of overexpression lnc-TSSK2-8 in HEK293 cells. (B) Flow cytometry analysis of cell proliferation. The transcriptional level of lymphoid enhancer-binding factor 1 (LEF1) (C) and β-catenin (CTNNB1) (D) in HEK293 cells with lnc-TSSK2-8 overexpression. (E) The influence of lnc-TSSK2-8 overexpression on protein expression and phosphorylation of β-catenin. (F) The influence of lnc-TSSK2-8 overexpression on the activity of glycogen synthase kinase 3β (GSK-3β). (G) The influence of lnc-TSSK2-8 overexpression on ubiquitination of β-catenin. *p < 0.05, **p < 0.001, **p < 0.0001.
FIGURE 3Differential gene expression analysis of lnc-TSSK2-8 overexpression in HEK293 cells. (A) Principal component analysis of RNAseq data derived from lnc-TSSK2-8 overexpression and control cell samples. (B) Volcano plot of differential gene expression analysis; symbols of the top 15 for each of upregulated and downregulated genes were labeled. (C) Gene Ontology (GO) gene set functional enrichment analysis of DEGs.
FIGURE 4lnc-TSSK2-8 activation promotes β-catenin stabilization through miR-6721-5p/heat shock protein (HSP)A6 axis. (A) The predicted miR-6721-5p binding sites of lnc-TSSK2-8 and HSPA6 3′ UTR. (B) The luciferase reporter assay we performed to confirm the interaction between miR-6721-5p and HSPA6 3′ UTR (B)/lnc-TSSK2-8 (C). (D) RT-qPCR analysis of lnc-TSSK2-8 level in response to miR-6721-5p overexpression. (E) RT-qPCR analysis of β-catenin level in response to miR-6721-5p overexpression. (F) Western blot (WB) analysis of protein expression and phosphorylation of β-catenin in response to miR-6721-5p overexpression. (G) RT-qPCR analysis of HSPA6 level in response to lnc-TSSK2-8 overexpression. (H) Confirmation of HSPA6 overexpression with RT-qPCR. (I) Confirmation of HSPA6 overexpression with WB. (J) RT-qPCR analysis of LEF1 level in response to HSPA6 overexpression. (K) RT-qPCR analysis of β-catenin level in response to HSPA6 overexpression. (L) WB analysis of β-catenin protein expression and phosphorylation in response to HSPA6 overexpression. *p < 0.05, **p < 0.001, **p < 0.0001.
FIGURE 5lnc-TSSK2-8 activation promotes β-catenin stabilization through the miR-491-5p/α-B-crystallin (CRYAB) axis. (A) The predicted miR-491-5p binding sites of lnc-TSSK2-8 and CRYAB 3′ UTR. (B) The luciferase reporter assay we performed to confirm the interaction between miR-6721-5p and CRYAB 3′ UTR (B)/lnc-TSSK2-8 (C). (D) RT-qPCR analysis of CRYAB level in response to miR-491-5p overexpression. (E) RT-qPCR analysis of lymphoid enhancer-binding factor 1 (LEF1) level in response to miR-491-5p overexpression. (F) RT-qPCR analysis of β-catenin level in response to miR-491-5p overexpression. (G) Western blot (WB) analysis of protein expression of β-catenin in response to miR-491-5p overexpression. (H) Confirmation of lnc-TSSK2-8 overexpression with RT-qPCR. (I) RT-qPCR analysis of CRYAB level in response to lnc-TSSK2-8 overexpression. (J) Confirmation of CRYAB overexpression with RT-qPCR. (K) Confirmation of CRYAB overexpression with WB. (L) RT-qPCR analysis of β-catenin level in response to CRYAB overexpression. (M) WB analysis of β-catenin protein expression and phosphorylation in response to CRYAB overexpression. *p < 0.05, **p < 0.001, **p < 0.0001.